United Kingdom | EnglishEN

Current country and language: United KingdomUnited Kingdom | English (EN)

ChinaChina
GermanyGermany
IrelandIreland
ItalyItaly
SpainSpain
United KingdomUnited Kingdom

YOU ARE LEAVING THE CURRENT LANGUAGE


MacuShield is now the UK’s most recommended eye supplement

MacuShield is now the UK’s most recommended eye supplement

9th Sep 2016

MacuShield is a once a day, easy to take, food supplement which combines all three macular carotenoids, lutein, zeaxanthin and meso-zeaxanthin, in a formula developed in collaboration with leading eye health experts. 


Scientific research shows that these three nutrients are found at the back of the eye, at the macula, where they form the, yellow in colour, macula pigment.  Particular concentrated at the centre of this pigment is meso-zeaxanthin.  The macula is a specialist part of the eye that is responsible for detailed, central vision
 
Macushield-Food-Wheel-(1).jpgMacushield-Range.jpg
Lutein, zexanthin and meso-zeaxanthin can be obtained by the human body from nutrition and diet. They are found in fruits and dark leafy green vegetables and meso-zeaxanthin is present in some species of fish and seafood.  The macula pigments in MacuShield are obtained from marigolds, specifically grown for this purpose.

Also available in the range is MacuShield Gold, which provides a fortified MacuShield formulation with added vitamins and minerals.  MacuShield Gold combines all three macular carotenoids in a unique formula in addition to zinc to help maintain normal vision, copper, vitamin C and a natural form of vitamin E, which contributes to the protection of cells from oxidative stress. 

MacuShield is taken once a day and MacuShield Gold is taken 3 times daily.  Both products are available from most opticians and pharmacies.

For more information, visit www.macushield.com

Notes to editors:

About Alliance
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH

You May Also Be Interested In...